Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Oramed Pharmaceuticals stock | $4.24

Own Oramed Pharmaceuticals stock in just a few minutes.

Fact checked

Oramed Pharmaceuticals Inc is a biotechnology business based in the US. Oramed Pharmaceuticals shares (ORMP) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Oramed Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Oramed Pharmaceuticals. Find the stock by name or ticker symbol: ORMP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Oramed Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.24, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Oramed Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Oramed Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Oramed Pharmaceuticals share price

Use our graph to track the performance of ORMP stocks over time.

Oramed Pharmaceuticals shares at a glance

Information last updated 2020-10-21.
Latest market closeUSD$4.24
52-week rangeUSD$2.3168 - USD$5.85
50-day moving average USD$2.8254
200-day moving average USD$3.3509
Wall St. target priceUSD$9.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.874

Buy Oramed Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Oramed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oramed Pharmaceuticals price performance over time

Historical closes compared with the close of $4.24 from 2020-12-31

1 week (2021-01-08) -5.78%
1 month (2020-12-16) 4.43%
3 months (2020-10-16) 58.21%
6 months (2020-07-16) 3.92%
1 year (2020-01-16) -18.15%
2 years (2019-01-16) 23.62%
3 years (2018-01-16) 8.34
5 years (2016-01-15) 6.61

Oramed Pharmaceuticals financials

Revenue TTM USD$2.7 million
Gross profit TTM USD$2.6 million
Return on assets TTM -16.58%
Return on equity TTM -38.78%
Profit margin 0%
Book value $1.465
Market capitalisation USD$65.6 million

TTM: trailing 12 months

Shorting Oramed Pharmaceuticals shares

There are currently 176,036 Oramed Pharmaceuticals shares held short by investors – that's known as Oramed Pharmaceuticals's "short interest". This figure is 8.8% down from 193,092 last month.

There are a few different ways that this level of interest in shorting Oramed Pharmaceuticals shares can be evaluated.

Oramed Pharmaceuticals's "short interest ratio" (SIR)

Oramed Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Oramed Pharmaceuticals shares currently shorted divided by the average quantity of Oramed Pharmaceuticals shares traded daily (recently around 222830.37974684). Oramed Pharmaceuticals's SIR currently stands at 0.79. In other words for every 100,000 Oramed Pharmaceuticals shares traded daily on the market, roughly 790 shares are currently held short.

However Oramed Pharmaceuticals's short interest can also be evaluated against the total number of Oramed Pharmaceuticals shares, or, against the total number of tradable Oramed Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oramed Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Oramed Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0086% of the tradable shares (for every 100,000 tradable Oramed Pharmaceuticals shares, roughly 9 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oramed Pharmaceuticals.

Find out more about how you can short Oramed Pharmaceuticals stock.

Oramed Pharmaceuticals share dividends

We're not expecting Oramed Pharmaceuticals to pay a dividend over the next 12 months.

Have Oramed Pharmaceuticals's shares ever split?

Oramed Pharmaceuticals's shares were split on a 1:12 basis on 23 January 2013. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oramed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Oramed Pharmaceuticals shares which in turn could have impacted Oramed Pharmaceuticals's share price.

Oramed Pharmaceuticals share price volatility

Over the last 12 months, Oramed Pharmaceuticals's shares have ranged in value from as little as $2.3168 up to $5.85. A popular way to gauge a stock's volatility is its "beta".

ORMP.US volatility(beta: 1.58)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oramed Pharmaceuticals's is 1.5764. This would suggest that Oramed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Oramed Pharmaceuticals overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, which completed phase II clinical trials is an orally ingestible insulin capsule for the treatment of diabetes; and ORMD-0901 that completed phase I clinical trials is an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site